SCHEMBL15869337

SCHEMBL15869337

[15NH2]c1cccc(C(=O)O)c1C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.63
G6PD P11413 1/20 0.52
CASP7 P55210 1/20 0.52
CASP6 P55212 1/20 0.52
ALDH1A1 P00352 3/20 0.50
ALOX15 P16050 1/20 0.50
CDC25B P30305 2/20 0.47
MAPT P10636 2/20 0.47
GAA P10253 1/20 0.47
NAPRT Q6XQN6 2/20 0.45
IDO1 P14902 1/20 0.45
AKR1C3 P42330 1/20 0.45
KDM4E B2RXH2 3/20 0.45
HSD17B10 Q99714 2/20 0.45
NPC1 O15118 1/20 0.45
CASP3 P42574 1/20 0.45
RAB9A P51151 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL48723 1.00 MMP2 (0.63) MMP2G6PDCASP7CASP6ALDH1A1
SCHEMBL27925721 1.00 MMP2 (0.63) MMP2G6PDCASP7CASP6ALDH1A1
SCHEMBL29367294 1.00 MMP2 (0.63) MMP2G6PDCASP7CASP6ALDH1A1
SCHEMBL26108766 0.98 MMP2 (0.61) MMP2G6PDCASP7CASP6ALDH1A1
SCHEMBL28508112 0.98 MMP2 (0.61) MMP2G6PDCASP7CASP6ALDH1A1
Hydrochloric Acid SCHEMBL2285638 0.98 MMP2 (0.61) MMP2G6PDCASP7CASP6ALDH1A1
Hydrazine SCHEMBL28369279 0.98 MMP2 (0.61) MMP2G6PDCASP7CASP6ALDH1A1
SCHEMBL8070950 0.98 MMP2 (0.61) MMP2G6PDCASP7CASP6ALDH1A1
SCHEMBL8070939 0.98 MMP2 (0.61) MMP2G6PDCASP7CASP6ALDH1A1
Hydrochloric Acid SCHEMBL28051606 0.96 MMP2 (0.59) MMP2G6PDCASP7CASP6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10919855-B2 Process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4yl]acetamide UNICHEM LABORATORIES LTD (IN) 2021-02-16 US claimed
US-20200181085-A1 NOVEL PROCESS TO PREPARE N-[2-[(1S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYLSULPHONYL) ETHYL]-1, 3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL]ACETAMIDE UNICHEM LABORATORIES LTD (IN) 2020-06-11 US claimed
US-11639332-B2 Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases Amgen (Europe) GmbH (CH) 2023-05-02 US disclosed
US-11549926-B2 Detection of nitrogen containing and nitrogen free explosives SCINTREX TRACE CORPORATION (CA) 2023-01-10 US disclosed
US-20220267305-A1 MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-08-25 US disclosed
US-11384063-B2 Modulators of estrogen receptor proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2022-07-12 US disclosed
EP-3341359-B1 PROCESS FOR PREPARATION OF APREMILAST GLENMARK LIFE SCIENCES LTD (IN) 2022-03-23 EP disclosed
EP-3878837-A1 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS OM Pharma SA (CH) 2021-09-15 EP disclosed
US-11040024-B2 Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione AMGEN INC. (US) 2021-06-22 US disclosed
US-11008288-B1 Methods for preparation of apremilast NATIONAL TAIWAN NORMAL UNIVERSITY (TW) 2021-05-18 US disclosed
US-10919855-B2 Process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4yl]acetamide UNICHEM LABORATORIES LTD (IN) 2021-02-16 US disclosed
US-20080085527-A1 Using luminescent based recipes for measurement of creatine, uric acid and glucose in bodily fluids INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2008-04-10 US disclosed
US-20080085527-A1 Using luminescent based recipes for measurement of creatine, uric acid and glucose in bodily fluids INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2008-04-10 US disclosed
US-20080027123-A1 Reduction of levels of tumor necrosis factor-alpha and/or inhibition of phosphodiesterase 4; treating erythema nodosum leprosum in leprosy, rhematoid spondylitis, hepatitis or congestive heart failure CELGENE CORPORATION 2008-01-31 US disclosed
US-20070287362-A1 POLISHING COMPOSITION AND METHOD OF POLISHING WITH THE SAME FUJIFILM CORPORATION 2007-12-13 US disclosed
US-7244546-B2 Planographic printing method and planographic printing plate precursor used therein FUJIFILM CORPORATION (JP) 2007-07-17 US disclosed
US-7244546-B2 Planographic printing method and planographic printing plate precursor used therein FUJIFILM CORPORATION (JP) 2007-07-17 US disclosed
US-20070128680-A1 Hydrazines and derivatives production process from hydrazines and dicarboxylic acid UNIVERSIDADE FEDERAL DO RIO DE JANEIRO-UFRG (BR) 2007-06-07 US disclosed
US-20070128680-A1 Hydrazines and derivatives production process from hydrazines and dicarboxylic acid UNIVERSIDADE FEDERAL DO RIO DE JANEIRO-UFRG (BR) 2007-06-07 US disclosed
US-20070004920-A1 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds CELGENE CORPORATION AN ORGNIZATION OF THE STATE NEW JERSEY (US) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11040024-B2 Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione PDE4A, PDE2A, PDE4B MMP2 65/4885G6PD 478/4885CASP7 341/4885
US-20200181085-A1 NOVEL PROCESS TO PREPARE N-[2-[(1S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYLSULPHONYL) ETHYL]-1, 3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL]ACETAMIDE BCKDK, DMPK, MYLK MMP2 3292/4885G6PD 2775/4885CASP7 3724/4885
US-11384063-B2 Modulators of estrogen receptor proteolysis and associated methods of use ADRM1, MDM2, ESR2 MMP2 2227/4885G6PD 4176/4885CASP7 3465/4885
US-20070128680-A1 Hydrazines and derivatives production process from hydrazines and dicarboxylic acid LDHA, CA5A, LDHB MMP2 751/4885G6PD 1379/4885CASP7 2145/4885
US-10919855-B2 Process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4yl]acetamide DMPK, BCKDK, MYLK MMP2 3292/4885G6PD 3186/4885CASP7 4003/4885
US-11008288-B1 Methods for preparation of apremilast APRT, ALDH3A1, TPMT MMP2 4282/4885G6PD 263/4885CASP7 2071/4885
US-20220267305-A1 MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE ADRM1, MDM2, ESR2 MMP2 2227/4885G6PD 4176/4885CASP7 3465/4885
US-11639332-B2 Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases PDE4A, PDE3B, PDE4B MMP2 222/4885G6PD 156/4885CASP7 138/4885
US-20070004920-A1 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds TNF, DHPS, IL1A MMP2 2700/4885G6PD 205/4885CASP7 1591/4885
US-20080027123-A1 Reduction of levels of tumor necrosis factor-alpha and/or inhibition of phosphodiesterase 4; treating erythema nodosum leprosum in leprosy, rhematoid spondylitis, hepatitis or congestive heart failure TNF, PDE4A, LITAF MMP2 235/4885G6PD 157/4885CASP7 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.